signature=06e97a2b16840469a54f58154cc3c417,Document

最新推荐文章于 2023-08-04 14:48:30 发布

weixin_39968801

最新推荐文章于 2023-08-04 14:48:30 发布

阅读量7.6k

点赞数

文章标签： signature=06e97a2b16840469a54f58154cc3c417

0001628280-20-010239.txt : 20200707

0001628280-20-010239.hdr.sgml : 20200707

20200707160511

ACCESSION NUMBER:0001628280-20-010239

CONFORMED SUBMISSION TYPE:S-8

PUBLIC DOCUMENT COUNT:5

FILED AS OF DATE:20200707

DATE AS OF CHANGE:20200707

EFFECTIVENESS DATE:20200707

FILER:

COMPANY DATA:

COMPANY CONFORMED NAME:Cardiff Oncology, Inc.

CENTRAL INDEX KEY:0001213037

STANDARD INDUSTRIAL CLASSIFICATION:BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]

IRS NUMBER:272004382

STATE OF INCORPORATION:DE

FISCAL YEAR END:1231

FILING VALUES:

FORM TYPE:S-8

SEC ACT:1933 Act

SEC FILE NUMBER:333-239725

FILM NUMBER:201016177

BUSINESS ADDRESS:

STREET 1:11055 FLINTKOTE AVENUE

CITY:SAN DIEGO

STATE:CA

ZIP:92121

BUSINESS PHONE:858-952-7570

MAIL ADDRESS:

STREET 1:11055 FLINTKOTE AVENUE

CITY:SAN DIEGO

STATE:CA

ZIP:92121

FORMER COMPANY:

FORMER CONFORMED NAME:Trovagene, Inc.

DATE OF NAME CHANGE:20130304

FORMER COMPANY:

FORMER CONFORMED NAME:TrovaGene Inc.

DATE OF NAME CHANGE:20110830

FORMER COMPANY:

FORMER CONFORMED NAME:XENOMICS INC

DATE OF NAME CHANGE:20040719

S-8

a070720s-8.htm

S-8

Document

As filed with the Securities and Exchange Commission on July 7, 2020

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Cardiff Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware27-2004382

(State or other jurisdiction of incorporation or organization)(IRS Employer Identification Number)

11055 Flintkote Avenue

San Diego, CA 92121

(858) 952-7570

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

2014 Equity Incentive Plan, as amended

(Full title of the plan)

Mark Erlander

Chief Executive Officer

Cardiff Oncology, Inc.

11055 Flintkote Avenue

San Diego, CA 92121

(858) 952-7570

(Name, address, including zip code, and telephone number, including area code, of agent for service)

With copies to:

Jeffrey J. Fessler, Esq.

Sheppard, Mullin, Richter & Hampton LLP

30 Rockefeller Plaza, 39th Floor

New York, New York 10112

(212) 653-8700

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated fileroAccelerated filero

Non-accelerated filerýSmaller reporting companyý

Emerging growth companyo

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.o

CALCULATION OF REGISTRATION FEE

Title of Securities

to be RegisteredAmount to be

Registered(1)Proposed Maximum

Offering

Price Per Share(2)Proposed Maximum

Aggregate

Offering Price(2)Amount of

Registration Fee

Common Stock, $0.0001 par value per share1,000,000 Shares$4.35$4,350,000$565

(1) Pursuant to Rule 416(a) of the Securities Act of 1933 (the “Securities Act”), as amended, this Registration Statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the Company’s 2014 Equity Incentive Plan, as amended, pursuant to this Registration Statement by reason of any stock dividend, stock split, recapitalization or any other similar transaction which results in an increase in the number of the Registrant’s outstanding shares of common stock.

(2) For purposes of computing the registration fee only. Pursuant to Rule 457(c) and (h), the Proposed Maximum Offering Price Per Share is based upon the average of the high and low prices for the Registrant’s common stock on The Nasdaq Capital Market on July 6, 2020.

EXPLANATORY NOTE

This Registration Statement registers an additional 1,000,000 shares of the Registrant’s common stock that may be offered and sold under the Cardiff Oncology, Inc. 2014 Equity Incentive Plan, as amended (the “Plan”). This Registration Statement relates solely to the registration of additional securities of the same class as other securities for which one or more other registration statements filed on this form relating to the same employee benefit plan are effective. Registrant initially registered 69,444 shares (on a post-reverse stock split basis) of its common stock issuable under the Plan pursuant to a Registration Statement on(the “Initial S-8”). Registrant registered an additional 34,722 shares (on a post-reverse stock split basis) of its common stock issuable under the Plan pursuant to the Registration Statement on(the “2016 S-8”). Registrant registered an additional 27,778 shares (on a post-reverse stock split basis) of its common stock issuable under the Plan pursuant to the Registration Statement on(the “2017 S-8”).Registrant registered an additional 111,112 shares (on a post-reverse stock split basis) issuable under the Plan pursuant to the Registration Statement on(the “2018 S-8”).Registrant registered an additional 1,000,000 shares of its common stock issuable under the Plan pursuant to the Registration Statement on(the “2019 S-8,” and together with the Initial S-8, the 2016 S-8, the 2017 S-8 and 2018 S-8, the “Prior Registration Statements”).

On April 16, 2020, the Registrant held its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). At the 2020 Annual Meeting, the Registrant’s stockholders voted affirmatively, among other things, to amend the Plan to increase the number of shares of common stock authorized to be issued pursuant to the Plan to 2,243,056 shares (on a post-reverse stock split basis) from 1,243,056 shares (on a post-reverse stock split basis) of common stock (the “Amendment”).

Pursuant to the Amendment, the total number of shares of the Registrant’s common stock available for grant and issuance under the Plan increased by 1,000,000 shares (on a post-reverse stock split basis). Accordingly, the content of the Prior Registration Statements are incorporated herein by reference pursuant to General Instruction E of Form S-8.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents filed by Cardiff Oncology, Inc. (the “Company”) with the Commission are hereby incorporated by reference in this Registration Statement:

•our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed on;

All other reports and documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that related to such items)on or after the date of this Registration Statement andprior to the filing of a post-effective amendment that indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, are incorporated by reference in this Registration Statement and are a part hereof from the date of filing such reports and documents.

Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

EXHIBIT INDEX

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California, on July 7, 2020.

CARDIFF ONCOLOGY, INC.

By:/s/ Mark Erlander

Mark Erlander

Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Mark Erlander, with full power of substitution, his or her true and lawful attorney-in-fact to act for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file each of the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as he or she could do in person, hereby ratifying and confirming all that said attorneys-in-fact or substitutes, or any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by each of the following persons in the capacities and on the dates indicated.

SignatureTitleDate

/s/ Mark ErlanderChief Executive OfficerJuly 7, 2020

Mark Erlander(Principal Executive Officer)

/s/ Brigitte LindsayVP, FinanceJuly 7, 2020

Brigitte Lindsay(Principal Financial and Accounting Officer)

/s/ Thomas AdamsExecutive ChairmanJuly 7, 2020

Thomas Adams

/s/ John P. BrancaccioDirectorJuly 7, 2020

John P. Brancaccio

/s/ Gary S. JacobDirectorJuly 7, 2020

Gary S. Jacob

/s/ Rodney S. MarkinDirectorJuly 7, 2020

Rodney S. Markin

/s/ Lale WhiteDirectorJuly 7, 2020

Lale White

/s/ Gary W. PaceDirectorJuly 7, 2020

Gary W. Pace

/s/ James O. ArmitageDirectorJuly 7, 2020

James O. Armitage

EX-5.1

ex51crdf070720.htm

EX-5.1

Document

Exhibit 5.1

Sheppard, Mullin, Richter & Hampton LLP

30 Rockefeller Plaza

New York, New York 10112-0015

212.653.8700 main

212.653.8701 fax

www.sheppardmullin.com

July 7, 2020

VIA ELECTRONIC MAIL ONLY

Cardiff Oncology, Inc.

11055 Flintkote Avenue

San Diego, CA 92121

Re:Registration Statement on Form S-8

Ladies and Gentlemen:

You have requested our opinion with respect to certain matters in connection with the filing by Cardiff Oncology, Inc., a Delaware corporation (the “Company”), of a Registration Statement on Form S-8 (the “Registration Statement”) under the Securities Act of 1933, as amended, with the Securities and Exchange Commission, covering 1,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), which may be issued pursuant to the Company’s 2014 Equity Incentive Plan, as amended (the “Plan”).

This Opinion is being furnished in accordance with the requirements of Item 8 of Form S-8 and Item 601(b)(5)(i) of Regulation S-K.

In connection with this opinion, we have reviewed and relied upon the Registration Statement, the Company’s Amended and Restated Certificate of Incorporation, as amended, as in effect on the date hereof, the Company’s Bylaws effective as in effect on the date hereof (the “Bylaws”), the proceedings taken by the Company with respect to the authorization and adoption of the Plan, resolutions adopted by the board of directors of the Company, and such other documents, records, certificates, memoranda and other instruments as we deem necessary as a basis for this opinion. With respect to the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity to original of all documents submitted to us as certified or reproduced copies. We have also assumed that the Shares will be uncertificated in accordance with Section 158 of the Delaware General Corporation Law, and the transfer agent therefor will register the purchaser thereof as the registered owner of any uncertificated Shares on its stock transfer books and records. We have further assumed that (a) shares of the Common Stock currently reserved for issuance under the Plan will remain available for the issuance of the Shares, and (b) neither the Company’s charter documents nor any of the proceedings relating to either the Plan or any of the award agreements relating to the Shares will be rescinded, amended or otherwise modified prior to the issuance of the Shares. We have also obtained from public officials and officers of the Company certificates or comparable documents as to certain factual matters and, insofar as this opinion is based on matters of fact, we have relied on such certificates and comparable

Page 2

documents without independent investigation. We have made such other investigations as we have deemed relevant and necessary in connection with the opinions hereinafter set forth.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when issued and sold in the manner referred to in the Plan against proper payment and consideration thereof and pursuant to the agreements that accompany the Plan, will be legally and validly issued, fully paid and nonassessable.

We consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.

We express no opinion as to matters governed by any laws other than the Delaware General Corporation Law and reported decisions of the Delaware courts interpreting such law.

This opinion letter is rendered as of the date first written above, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. Our opinion is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company, the Shares, the Plan, the award agreements related to the Shares or the Registration Statement.

Respectfully Submitted,

/s/ Sheppard, Mullin, Richter & Hampton LLP

SHEPPARD, MULLIN, RICHTER & HAMPTON LLP

EX-23.2

ex232crdf070720.htm

EX-23.2

Document

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

Cardiff Oncology, Inc.

San Diego, California

We hereby consent to the incorporation by reference in this Registration Statement of our report dated February 27, 2020, relating to the consolidated financial statements of Cardiff Oncology, Inc. (formerly Trovagene, Inc., the “Company”). Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

/s/ BDO USA, LLP

San Diego, California

July 7, 2020

GRAPHIC

image_11.jpg

begin 644 image_11.jpg

M_]C_X0G*17AI9@ 34T *@ @ !P$2 , ! $ $: 4 !

M8@$; 4 ! :@$H , ! ( $Q ( > 1L !0 $ $F 2@ P $ @

M @$ ! $ $N @( ! $ B4 $@ ! 2 '_

MV/_M Q!9&]B95]#30 !_^X #D%D;V)E &2 ?_; (0 # @(" D(# D)

M#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,

M# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,

M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\ $0@ %0"@ P$B (1

M 0,1 ?_= 0 "O_$ 3\ $% 0$! 0$! , 0($!08'" D*"P$

M 04! 0$! 0$ 0 " P0%!@/S1B>4I(6TE<34Y/2EM<75Y?56

M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1 (" 0($! ,$!08'!P8%-0$ A$#

M(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A7U5F9VAI:F

MML;6YO8G-T=79W>'EZ>WQ__: P# 0 "$0,1 #\ [+ZX_6Q_U>KQZ\>@7Y.7

MO+#8=M;&LV;W/CW/_G6>SV?\8JW2_K#];K,VBO.Z73D8606@Y>#8'L8'$-]1

MSC9:VST_\(S]SZ'J)_KQ5U.QN.*ND4]8P!K:TAYOK=.OHFE[+6>K7[?4I]3_

M (5RD,]1WMK:[]&U;V-]8>B96!9U&G,J.'28MN<=@8?W;6V;'UN]

MWM:]LRSWN1EBPDFIW:QJX0]-ZCGX&)TN[I75KG8XVFJQV/C8["!LW8^2

M_$=8YEGY[;G_ /L18H9=3\+Z\FMN$>JG$KJ!Q7.#WV"O$J:ZS=8QK;KJOY[^

M9_2O_P 'O2^[8R2+.D92KBC^CMJHYY@ T-91C=2_2W>^Q_K5]7\G"OSJ,UC\

M?% .0Z'!S ?HN?2YHNVN_,=Z: ?KQ]5 6 ]1KFSC1^FNW])[/T/_ %W8N&;T

MOJ(HZ_UJ[IQZ7AVXME=>,\;"'664/:RNIP:_8STO4>_TZZ_4_F4'&JS[W8[%_26U5^BB.6Q_O'YA'YH>FQ_W*#S&

M3307PF6TM:/_ '3Z3U+ZR]"Z6RI^=FUU"]N^H EYW$SF6.K8ZQS2',=L8-UCFMM8QS]C?I;%Q>9TCZQ],=T>IV)==CX^.

MP6WX---V4QX?;:^BO)MKN?5]E]9C,?\ [3?N>_Z$,3I'7G_6<9F1@Y@KLINV

MVY!9:_W8MU-/KWXX92VU[MK/3_P7\TFCE\?"3Q]"01*.O#_57'/DL#AZ@$5J

M.(/M2[IN35F9M !902YC;/>VM_I7%FRW:UV_]#ZBP_JQ]4+[?JYU$96&<7J]@LIQ

M+KP0YK'4L9M;]+TZ['67U6O:LVOIO6F] R>BGZN/.6VSU#U"&[@ ]KOT;_\

M#6-;^@9]FNV>A_US>1AP\1J1/#("C*(\Y?W42RY>$: &0)T$CY1_O/1GZ]9@

MZ;T_,&'7NSF7/>TV. ;Z5OH#:?3]V[Z2T[OK36SZN5]8;6TW6D5C'+M/5G9;

M7OV_1KV6V?0_FUR]/1NL-Z;T&LX-Q?C^KZ["T>S=DBT"W7\^KW_U%?Q?J[U

M=>&%;2_]D8^59EL= ],@M!J8#^'B4YN3D-KQL@ TV$&

M';F^JV('^C&YT5OAKGAK;V6^EK[GL]7>K/56]>ZE

MT/$PF])OK;A ,+S&Y[FU.I;LJ=LL;7M^DYWY_P"C35SM9/UKOJZMEX->.Q]6

M/0^]EN\@NVT-RV@MV>W=OVJLWZYY;^G59GHXM3K+;*BR^]S!%;:WAS'"E^_^

M=]ZIY/2NJ.ZYFW-Q+359A/K98 (+SB5U!@U^EZH]-9]W1.LGHN-2,&XVMR+W

M.9M$AKF4!CC[OSMCDE/;7?63H5%UU-V;779CSZK7R((@;?>_W?08C]/ZOT

MWJ8>G=(R'?6_-R']9.HV/Q7T8CA:VAY #"WUMU;:X_-]/Z""G_]#U5)?*J22G

MZJ27RJDDI^JEBC_FK_SE,>A^W^_^F_FF_P#NKM_ZVOF])/A^E\WRGY?^Z_J+

M9=-MQ\W_ '/]9^GNK?LW]FW_ +5V?8-OZQZGT-LCZ?\ :4.B?LC]FU_L7T_L

M$O\ 3]+Z$[G>KM_Z[O7S(DE_D_TOF_ZG_P"CJ_3Z;?X?_HK]5)+Y523%S]5)

M+Y5224_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/_]G_[1TB4&AO=&]S

M:&]P(#,N, X0DE-!"4 ! .$))300Z

M "; $ $ MP'1E96Y"

M:71B;V]L MP7!E96YU;0 I%4VQI8V54>7!E $EM9R &8F]U;F1S

M3V)J8P $ !28W0Q ! !4;W @;&]N9P 3&5F

M=&QO;F< $)T;VUL;VYG / !29VAT;&]N9P '1415A4 0 "6AOD%L:6=N !V1E9F%U;'0 )=F5R=$%L:6=N96YU;0

M ]%4VQI8V5697)T06QI9VX '9&5F875L= MB9T-O;&]R5'EP965N

M=6T 115-L:6-E0D=#;VQO7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W

M$0 " @$"! 0#! 4&!P/S

M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$

M A$#$0 _ .R^N/UL?]7J\>O'H%^3E[RPV';6QK-F]SX]S_YUGL]G_&*MTOZP

M_6ZS-HKSNETY&%D%H.7@V![&!Q#?4;ZW3KZ)I>RUGJU^WU*?4_P"%7,]/Z%GW?6##R>B=)S.BTU/8_)?D

M/< &AP-NWUMMEC'5;J_0_2^M_P &K>.&,XM1$&I7(G[/TN*/^*UISF,NA-6

M(C\?[ST73?\ B/R?0,.RF]N1CWUU6PPVM8W*J>RMSW;-U7K

M,L][D98L))J7!P\'7T^O= RY0!<>*^/S]'RO=X_UX^JF3>,>KJ-?J.,#>'UB

M?^,M8RO_ *2/F?6KZO8.7;AYF;71D4#=;6\.$ M%H]VW:YSJWMVL:N$/3>HY

M^!B=+NZ5U:YV.-IJL=CXV.P@;-V/DOQ'6.99^>VY_P#[$6*&74_"^O)K;A'J

MIQ*Z@<5S@]]@KQ*FNLW6,:VZZK^>_F?TK_\ ![TONV,DBSI&4JXH_H[:J.>8

M -#648W4OTMWOL?ZU?5_)PK\ZC-8_'Q0#D.AP

F@'Z\?5

M0%@/4:YLXT?IKM_2>S]#_P!=V+AF]+ZB*.O]:NZ<>EX=N+977C/&PAUEE#VL

MKJ7,/^$8RD6/=7_PGT$+ ^MWU'VVOHKR;:[GU?9?68S'_

M .TW[GO^A#$Z1UY_UG&9D8.8*[*;MMN066O]V+=33Z]^.&4MM>[:ST_\%_-)

MHY?'PD\?0D$2CKP_U5QSY+ X>H!%:CB#W.%]:_J]GVU4XF=7;;>YS:V .#B6

M,]>P[7-;L8VK_"/_ $:SNI_7[H=&'DNZ;DU9F;0 64$N8VSWMK?Z5Q9LMVM=

MO_0^HL/ZL?5"^WZN=1&5AG%ZO8+*<2Z\$.:QU+&;6_2].NQUE]5KVK-KZ;UI

MO0,GHI^KCSEML]0]0ANX /:[]&__ UC6_H&?9KMGH?]F]!K.#<7X

M_J^NPM'LW9(M MU_/J]_]17\7ZN]0'7AA6TO_9&/E69;'0/3(+0:F _G._FJ

M-G_'*MD $Y ;"1KRML0),(D[D"_-T^D_7*G)JR+^IMKPJJ75L8\.YM3J6[*G;+&U[

M?I.=^?\ HTU#7CL?5CT/O9;O(+MM#6_I

MU69Z.+4ZRVRHLOOJ>3TKJCNN9MS<2TU683ZV6 ""\XE

M=08-?I>J/36?=T3K)Z+C4C!N-KJI?5OIF7A_63J-C\5]&(X6MH>0

M PM];=6VN/S?3^@@I__0]527RJDDI^JDE\JI)*?JI8H_YJ_\Y3'H?M_O_IOY

MIO\ [J[?^MKYO23X?I?-\I^7_NOZBV73;-_P!S_6?I[JW[-_9M_P"U=GV#

M;^L>I]#;(^G_ &E#HG[(_9M?[%]/[!+_ $_2^A.YWJ[?^N[U\R))?Y/]+YO^

MI_\ HZOT^FW^'_Z*_522^54DQ41I=&AE4]B:F, !

M $;G5L; , -3F%M94-O;7!A=$UA8V)O;VP #DYA;65#

M;VUP87153DE88F]O; $ 13F%M94-O;7!A=%=I;F1O=W-B;V]L !-/

M=71P=71-=6QT:7!L949I;&5S8F]O; 84V%V:6YG1FEL94YA;65#;VUP

M;VYE;G1S5FQ,

'1E;G-I;VYS8F]O; 0

M1V],:79E0V]M6QE'1E;G-I;VYB

M;V]L 0 !9-971A9&%T84]U='!U=%-E='1I;F=S3V)J8P $ 1N

M=6QL " M!9&1#=7-T;VU)4F)O;VP! !T%D9$58249B;V]L 0

M 9!9&1835!B;V]L !-!9&1835!3;W5R8V5&:6QE55))8F]O; +

M0V]L;W)0;VQI8WEL;VYG Y-971A9&%T85!O;&EC>6QO;F< #

M #U=R:71E36EN:6UA;%A-4&)O;VP! %E=R:71E6$U05&]3:61E8V%R

M1FEL97-B;V]L =697)S:6]N;&]N9P .$))30^B (;7,T

M=P (X0DE-! 8 < !P $! /_A$(9H='1P.B\O;G,N861O8F4N

M8V]M+WAA'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP

M0V5H:4AZDY48WIK8SED(C\^(#QX.GAM&UL;G,Z>#TB861O

M8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,"UC,#8P

M(#8Q+C$S-#&UL;G,Z6YT87@M;G,C(CX@/')D9CI$97-C&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA&UL;G,Z>&UP34T](FAT=' Z+R]N&%P+S$N

M,"]M;2\B('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA&UP

M.DUO9&EF>41A=&4](C(P,3$M,#4M,3)4,38Z,#$Z-# M,#&UP34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@&UP34TZ2&ES=&]R

M>3X@/'AM&UP+F1I9#HT.3)"

M-$8W0C X,C V.#$Q.3$P.4,S,T1&1D0P,#!$,B(O/B \+W)D9CI$97-C&UP;65T83X@(" @(" @(" @(" @(" @

M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @

M(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^(,6$E#0U]04D]&24Q% $!

M ,2$QI;F\"$ ;6YT", * M #( -P [ $

M10!* $\ 5 !9 %X 8P!H &T &!YD'

MK >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$ DE"3H)3PED

M"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+

M:0N "Y@+L O("^$+^0P2#"H,0PQ#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0

M"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C

M$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5

MFQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO

M&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<

M*AQ2''LP>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_

M'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0C

MPB/P)!\D321\)*LDVB4))3@E:"67)< ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!

M*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P

M1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,%W)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B

M8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI

M0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1,QY

M*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K

M@%JX8.AG*&UXD :0;I#6D3^1J)(1DGJ2XY--

MD[:4()2*E/257Y7)EC26GY0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+

MIOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[ L'6P

MZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LN

MNZ>\(;R;O16]C[X*OH2^_[]ZO_7 HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFENV]FWV^_>*^!GXJ/DX^4E:2EM+7$

MQ=35Y.7T]9:7IJ>VM\;'UM?FY_;W:6IX>7J(B8J8F9JHJ:JXN;K(RKX^?H1 $# @,$!P8#! ,&!PH6&AXB)BI25EI>8

MF9JCI*6FIZBIJK6VM[BYNL/$QKU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>Y

MZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[

MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7

MN>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU

M>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7_]#?XYZO

M53Q^+3^*UE[\.C)66\NY2R_29_\ 41U+@FQ')64\:DD7#,+PV"0P/B>)"F=)

M6B,H,P 5A=G';%O+>K)5=K3U(.@#_2P?:2:!F'\0GU[P313IZV^K;/"RRHLW4?.

M$B$J;CT3> &?SS_ /JJ_P#"H\GI

ML_'I_$&Z$9APN;.?4E?4/D2!HX\7R1U;@@FJ)H!97,&+4L4=;%-M'NO(\J!O

M>:-]00/O)V"[OW[9[MON'."D?-)\)'D >L4.MV>W[>*P8*6EJZG!,;HJU**JHZN

MGG62)Y() ZZ@JZV=;JRGF).5=GYMMZFLLO1*2L P2 I)$@@[<1[-FVLO.]#O5'.76WT>^FKJ[U#Q"/%L]=

M2,F8#G'-F)TM/#2QSU]=0QSS.L-,J1H"S$A5 \.8/;\96S8YQ,N.-I43$8D8X"C4KW/5ZOKW/5ZOKW/5ZOKW/5ZOKW/5ZOK

MW/5ZOKW/5ZOKW/5ZM"[U&?CJ_B1]//4)UWR!E7J]A5%E

MC(V6[G87NW<9>PZM

ME14MM*CXU;2D$\>FL!-Y.WG>6VS&X:;>2$(<6D>!.P*('#HJ_G\"GUQ>HWUP

M])^N^:O49FVES;C61LPX;E_+E1A>$X;A*PTM3AIJ9%9,-AA5R7%[L">0%VZ[

MCY=D=VPBS04I6DDR2<08XDUD%V#;]9EGMI0GW8J>)IRP?\9'UQT6+X568KGS#,9PNDJ8*G$L(?

M+V"PBKIXY5>2$R0TRN@D4%=RD$7N->:[L5Z:V],D9PP'J%DW*>?=

MAO\ ZC. ?^YZO5[GJ]7N>KU5S

M_B@^H;JGZ9?390]1^D&-PX!FR?,V%Y;DKJZBI*]#255)62R+Y58DB7+0KK:X

MMRZ!)KQK7I_X>']>7_;SL-_]1G /_.7CW=BM35OOXM7K0]0/I1S%T2P_HGFF

MERY2YUHL-$;]&WXGWK%Z

MP^J#HKTRSYG^@Q/)^>*+!,EX)18)68=AU9@F$ULB25N$P5H7.73_K+G&DS#E?!\F8CG&@HJ#!\,P]UKZ?

M',(HD%7^\:K=>YZO5[GJ]7N>KU>YZO5[GJ]

M7__1W^.>KU:&'_"DW*&G:/#JFLIJN!&(

MLKQSL7=!V$BL?MCF>7TVWC*\@4VD^-+BM0\P"#ZC">H]%8"?4O9O(W@2XH>!

M;:=)\B01Z'&.L'C54/HD]0V2O2QZE>G/7#J#T:PWKQE;)TM0]?T_S.8UC8U-

M,],E5 :B*>+YBF9Q+#YL;+N4?9;:ZROOMN\_FN6N6S3Q96J/$.HS!VL,'V

M[#$NX^\3&59FW=/,!Y")\)ZQ$C:)&T2#Z;1N!2_C3_A#>L3IGB/2?U$8=B60

M,O9EH)HC$>NERDD.B@7/N]

MK&>?]LF^UC_Q1;AD3M+:@/($D@^VBO=_L8W'OO\ B>Y+QC8'$D^9 (]E&\]

M77H[Z)>B+\(CUH](>@F&8AA.2\3P;$,[UU-F/$ZK%9GQ*J_E]%+*)*HDH&CI

M(_<0! 02!=F)"&Z.^-]G>]UE<71!6%!. P&H\/,X[:&.^&YMCD>Y][;V@(0

M4E6))Q.D';Y##97SXN=!JYWU=AC?XYOJQROZ=>A7II]-U33="\J](HE66OBEAHZ6

MZM2@G$)2"9&S$GIDQU<3-[_;MF[66V]E9D,H:0E)5 *E$"#BT_R^-XBF)T.YI!(1\EB4PR/=6SM^#G^-GG7U?=2*/TM^

MI[",-AZN8I05>*=-^IF5H1009A?#:9JRJHZVB4F..K$$&478SVX/YQ?AVX1A62,O8!#U1]1N(8K+#>3RWD1A%!'9Y=K>]&H#$&=EG9%^O,M\J[#=V;5$?E^\/2LDD

M^D@>P"L0LU[=MY[IL%7M)H.Q^*5^*-DJ2#$*_U39^PT8E.^*T

MCYI83P2N2-PC3$Z>1#&+?Y-1L'^'7AA_L6[KOX"U;,",/T.WKVT7?[*N]3&)

MNW1)G']1LZME6:>CG_A2/ZBLBYGP7+OK%P6BZV=.*R9*;&'1L

M=IG2'#Q34%6J#4Q>5$S?\6>!C/?'Z;LN?:4O+U%IP;$DE2#U294/.2.JI/W,

M^I;,F'4HS%(>:.U0 2L=IM-38J]!D

MW,G2_J5A-)AN*P&CQO.6#89,PIL8IZF!BU/5RQ,DL19&)T5UTQU[-]T&[C>A

MK+[]HQ*PI))&*4*(Q!!V@' X^59']I>^+EONL[F&7NB804* !P4M(."@1L)&

M(P\ZTZ/^'X/Q6O\ N*G_ -8?IO\ ^X_S,3_8(W4_YE?][?4'O'=I2EMP- Z0)48Q))&$G&$A(%!)TU_&W_$QZ:YAIL2/Q&LD8_AN)8!#TZZ^].H8*

MO/V0:2=IJ.KHYF$*XGAC3$R&F,AV21O=HF*JS,&5FP[[5.RM_=Q])"M=NO[5

M<0?Z*N$QL.PCH@BLR^RCM78WD84E2>[N&_N3P(_I)XQ.T;0>F03K)>L/\:3\

M2_I9ZN/5+TQR'ZE/Y%D;IQU&SOD/)F!_U.R!5?)X3@^9JW#Z2#SJS YII/+A

MA5=\CL[6NQ)N>9-;G]B^[-UE%J\[;2XXTA2CKW9T:?R:(

M]9]LS07/;+O/KU?G%SZ1[(CW5>-^&C_PH6SOG#J1E;H=ZZ%PRIHLZ5,&7LK]

M?L HX,):CQ&H<11)C5+3;*;R)G(7YB".,1$@NA0L\N46N:1"S < B"=FL#"#T@".(C$7I?B:?B%9

M2_#JZ!0]3<1RZ,\]0,Y5W]3^EN0VJ#2Q5N(>0U1+45,JJ[)2TT:[I"JEF8I&

M"N_>L%]F?9Z]O%?]R%:&TB5JB8'0.L\/4\(J>.T_M$9W;R_ORG6XLZ4)F)/2

M3T#CZ#C-:6G5O\=+\2_JOBM36Q=>QTNP>9FDIWUF^:64=A>[-H@#\OWAZ5DDGTD)]@%839OV\;SW:R?S'=IZ$ #U@

MJ]JC032>O+\5.++QS;+ZD>L,>557S&S-)BF8AAX4B]_F3^CM;_6X;#=4N=

MW^68U]$)GV;:*#O_ +V!OO/S+^CIE4>W90I=*/QR_P 2_I7BU-7-Z@GZEX5$

MZRU>5^J^$X7BU)4A;>Z\Z0P5J VU\JI0\*\V[#=V;I!'Y?NSTH)!'I)3[0:-

MM'JGZ>8<>F_5/IGEK.-!

MF7 [T]?%@^;,!RTV+134XJD=9J=_-AFB$T9T)1@VTDX?;R=G)R;>-FQ>/>-.

M+1!V2A2H@QL.TUBLR-V>T@9UNT_?,CNW6T+!&W2M*9D3M&PB1U&8K3^_X?

M@_%:_P"XJ?\ UA^F_P#[C_,O_P#8(W4_YE?][GKI=TTRAF&EP[K11T^*S=9?4)BV#8"V(XE4U&.5TE#3X;A

MU-1QX=2Q08>U/&\IIR[N"0$*EY Y9_3ODB<22R2-#84J D25*)U$E4D

M"8 Z=@$E[]1N>*RYIEM0#X!UN%*9)*C 2D#2 $P"8DGHVF\/TE?B@5/1;\(#

M*OK0]6NR\7N^"\NL$!ML)23M(2G2)4>)Q.&.)(Q&VITW0[4C8[G(S+,%E

MUPJ4 , 5*U&$C@,!CA@ 5>NF?;8,SS[21=44&W,D=W^PW=VQ; 4SWR^*EXSZ?:/9ZFL:

M=X>W;>._=)2_W*."481Z_;Z"H/07\J;X4,"?J5F+&\_M@:S_,BC.,

MXG-B)@$QCB\SR_.V[]BWM>P[HGJ/P7HWA%<973BGC\=K!Q[1QQH85XU3--2U-/'233P/#%7QFJHI)%($L0E> LA/<

M!XV6X\01X<7(OY1@6&?+25L]:DQO@]%2%]PA71

MR;6TMKRCB0*\*L_]6>>I^6K*6D>

M6*3RJN.6)]K ':Z$'Q'*)&-;K4R_X=K_ !!O^X@/_64R3_YY^/\ =BM35EWK

MLZB9QZM?A%^G[J1U!QC^?YTS?C67L7S%C/R]+2?,5#4V+(7\FBBAB311HB ?

M#E$#Q5ZM;;CU:K82_'X_YB_TS_\ >MS/_P"56&\::K9JL'\.?_J]_P!-G_@Q

MP?\ E/-RZ]E:%6;?B2_B"^KSH%ZML]=,>DO5S^J>1\&HL#J\-P3^098K_+DK

M,(IZJ8^=B>'5$QW2.38N;=A8=,B=;NJ']=N1< CSB0!7A1#^MW

MXI/KMRAUHZNY3R[UT_EV7\KYHQ_+N!8?_5C)TWD4=%BL]-#'OGPEW;:B ;F8

MD]R2>6#8KTTI.F_XU/JER?D3.^'9SJ:/JQU#QNHHQDO,F9\.PK#L/P.DCBF%

M232Y?I:!JF21F0IO@5J:--Z9OQHO4+D/-F%X=ZA*R'K!TXK9HJ;

M&*\4%#08[AL#,%::FDPZ.GBGV EC',A+VL'3OS2FQ6YK:ZPG%'%HC$TMTXC#

MT^>M[IJ.F'J!R8,Q8512MB>6,PX9*:/&_M%Z2VW<7:-0&((P4D](/#X'B

M#6M?UF_X2X5HJZRN]/7JHBDH)"WR&6.LV".DT0'V?,Q3 Y&62_C:A2WQO89)

MY-]428 N[7'I0K_0J_PC6,V=?2NJ2;2[PZ%I_P!$G_!%5==9OP"_Q)ND%!B^

M,472["NL."8)')5UN(='<=I*^9H8@26@H<4&'UTY/@D5.SG_ \E#)NWS=N\

M4$ETM*/!:2/:1J2/,F*BS.OI^WFLTE0:2ZD<4*!]@.E1\@)ZJIUPO%,;RSC%

M%B^"XC59>S!@DZ5F'8IAI!CFBDE(O((P[%G9SS$;/-QK;)M^;%5LG2T\K4$\

M$D2% =6P@O:">,2<9K4!YE]6'-

M?03_ :/0%Z:^G/H@Z)=4,9Z2X!GCJMUMP6#J5F_/>

MOCE^7@AIVC1HXMH=P7:Y.G/SMEW_ ,RNAOIWZ[]#\[]%<

MAT'34=:,'QJJSIE;)]+#080U?@M72QK5PTE.%BADF2LM*(U56*![;V=FGCZ=

M-Z[[,;!]NYI/XB'K*Q[,M6]76X3

MU"S+T_HFF0D(264;PK*]OYDK&8V7Y9ZY+"%'$@A)4/

MZ,GAT@;>.%,[@YV_EM[^99M1>G>9

M^E'5W\.'+6>\@YPIGPS',O8[E+/LL3JZD+)&35[HIHR=T4J$.C ,I# 'D,Y1

MV,9%87"7[?,EH<29!"V_PQ!X@X$8&IJSCMKS[,+9;%QEB%MJ$$%#GXX$?2GJ=EG&,N4O33.63Y\B09OH:N@:/#,;SSEFN

ME@@2K2,F-:M9Y20/M2GD"YNS:*[0[!]A25%QM>J"#BEMP28ZH'I4_9._=I[.

MLP8?2I(;<1IU C!3C9@3PF3ZUK:\R2K&BOH:?AC?AD^B_('HWZ$9JQSHAE'K

M-GWJYE+!.I>=NH?4? \+S%-45&8\*AQ*2FI'Q6"80TD2SB%$C5 ZKNR_LOR2WR6W<4PAUQU

M"5*4I(5.H P)!@"8 $3M.-:R/X]?HUZ+>D/U892'0K"Z;)V3^L67!GZMZ;88

M_P#H^#8C%B-103-21=X:2H$:M'']E7$@2R!57)KL%WRODCB>B)QQ.+_;]N78Y/FZ/RH"4.HU:1L29(,= / =,QA@ Q_ HSQC^2_Q

M/?3M3X+5M!19X&8LCYFHU8JE505.6ZZJ$;V[A*BFAF _Q(.&G;K8MO;L7)4,

M4:5#J(4!\"1ZT5]@U^XQO3;!)P7J2>L%)/Q /I10OQ!/^K]?6Y_X5[J5_P"Q

MGB/!?V??\L&Q_P!H:_WQ- _M#_Y;]]_M[O\ OZJN._X3O>AKT^>J+.W7SJKU

M\R=A_5&GZ+IE[!\G].\U1BKPHUF/?S"66MK:-SY=0$2A\N&.97C)9V*[E0B'

M/J'WYS#*V+=BU66^]U%2A@83& /#;)(@[,8)J9OISW$R[-7[A^[0' UI"4G$

M2K5B1L.R #(Q.$@5;#^.#^'3Z2D]$O4_U!9!Z0Y;Z-=4^BZX5CF%9CZ<830X

M%%BE+4XM281+0UT&&I!%/O2H'DNZ&1'555@I93$_8?VBYM_.VK1UY;K3L@A1

M*H(!,@F2-F/ @F)8C2XCB.)56!86F

M,U\LU'4TL86^4N]PTEPZU0" I6D0

M023B8 CKBLYM[-YL@_LWE]QFS/?O*;&A,D$DI3J,@@ 2!),]4XUKN)^(?T%R

M9U"R_GST^?AA=)LBXYEFN@QC*G^Q&1![/+]ZW4U=YH\M*A!TAM&'^E41[:QS':-E[%PEVTRMA"DF1J+B\?],D'

MV58C#^,Q^-3GS JE,O>E^GQC"\37Y$XGE[I/FS$(F$B*Q0;ZBIA?>CBX93=6

M[:CD>*[&MRF'!KNB".!=0/D#4BI[:=][ALZ+4$'B&5GYD5KB]16Q]NH.>FS7

ME1,AYI;&<4;,N1Z?#GP>/!L0-;+\Q0K02!6I13R;HA 0#'MVD:,C&>.VL;6D.$Z4H@8))3))"N(.$

M;... )?CD]#\N^C#!/1KZ).F&8,=QWI%TWP7-O57!J_/DU%/7U.(YKS&WG^?

M+AU+10R& 4EH[0KM5SW+$D[[#L\%$7;M

MD3>2(LLL84I3+:5K&J))6K&8 &$882/VE[P7&5Y%<73']T0

MD1Q@DA,^DSZ5&W9EN];YKGUM:OG]FM1GA("2J)ZXCUKZ"^=?PV_0CGKICB'2

M3$_2ID?"LIUM$H@F".J*Z&WW9ID#]J;=5HV$$1@D CK"@)!ZYKYH?5O

M)E%TXZK=3>GF&XPN8P?%,LYSPRCW&2:/YE9,.Z?Y$RCEOYJ-2OS,\%"WS%202;-/,7E8>UCR

MJ#(K9J=^$I_VBWU-3USCU:K82_'X_YB_P!,_P#WKRMFAJ_ E_ZNYZB_P#A.,7_ /8F

MP#FG=E>%5?\ J3_ZN*Z^?^#KFK_R^U7+C96JMC_!4]+W2CK-FKJUU0ZIY6H\

M\?YL?Y/A.4,M9C@CJ\/2KQ,583D[J-TP&&XOA&9K__3W^.>KU?/8_'&]*_6?TW>L+JGG+$ZC%\3Z$^H

MW&:WJED7,+SULV%?/8K4MB>(89+O)BCGIJII&2*_^1,;CQ"]".P[>JRS+)VF

MTA(?82$*&$P! 5TP1$GID5SN[==U+W+,Y=<45&W?45I.,23*D]$@S Z(-$2]

M%'KKZ_>@?J=6]3NA&+42U&/4J8#G'*&;:5JW!L:H8YA4)%50Q20R HXNDL4B

M2+=@&VLP([WUW%R_/[4,W0.!E)!A23U'$>8((ZL!0"W(W\S#=^Z+]J1XA"DD

M2E0VXC ^1!!Z\35S6;_^%/'JLQC*>(X3E+H3DG)F:JV TE-FZ23%\26CE="I

MFAI)YD0NI.Y!(SJ#]I7%P89L_IBRI#H4X^XM .S 3U$Q[8@]$5--Y]4>;+9*

M6[=M"R/NQ,=8$^R9'3-:VE54XUFG':BLJI*C'LQ9CJWJ:B9M]15UM;63%V)M

M=GDDD?Z23S))"4--@" E(] !^%8T+4MUPDRI2CZDGYFMP#HWZ)139D,WEL R$FX3I>>25$<4C )!Z

M]I/1,'$5IT\S$K#.OIX_AB?]F\?1A_X3G*W_ ):XNT[_IXKW_ &U?QKJ+

MV7?].Y9?[4CX5KF_\*FO^8]]&O\ WJ,Z?^5N$H3.OK!Z?Y;JLR="NM%0F9[1FQ";XY[ ^T:VO,O1E[J@E]H0D'^-/".M(P(Z #TQ)'U

M]FUS9YBO,6DE5NZ941_ KC/4HX@])(Z)JG]!7KPZO_A]]:AU=Z5PTN/46,4;

M98S]D',1D&'8YA;RK/Y;M$=\4T3H'AF35&N"&1G1I6W]W#L]X++\N_((,I4-

MJ3\P>(X]1 (B?OOS#$*!$*2=BA\B-H/#K!(-\W5K_ (5%YOQO(5=A

M71?TKTV0NH>*4ST\.;L[9G_GM%A4SQ;?,AHJ?"Z'YED9B4,DB+=1N1@2H@;*

M?I=918,.RGEO-.$=1LT9GJ(,)R[ERCR/A=575%5(Q1(::#"8(7D>0L!

MMLQT%K:W'5]V";J-MEQ:%(2D23K($=)))B@'8?4!O8XX&T+2XM1@#NP23T

M"9J^C\19O5/4_@1]TZC(H Y#6^/

M8;DVH$$2.H^0

M(%5Z^J?U4]9_63UBQOKAUUS&N/YRQ>*'":.GH(OEL.PO#:8NT%#0T^YO*IXS

M(S!;DEF9V9G9F,A[J[JV636:;:U3I0,>DDG:2>)/X 8"HZWKWKO-9

MHQ6BEPB1*;=99(Z.EJ)FE?4+*T8%VN4@SZC-]F+?+?YT/_EOWW^WN_[^JN_1EZXO4!Z#^IU3U0Z"

M8]2TE;C%*,$S9E3-%.];@F-4:R>W*WZS#(+HOVB@"1!!$I4.@C#T(((Z<31IO7

M7^,CZL_7MD>CZ5=0(,O].NEE]'74Z8M5TI$D+U]1B5762R+%)=

MXXD9([[2RLR*P"VXO8WE.0/E]K4MV" I1& .V )XG$^0,4*]_>V?-]X& P

M[I;:D$I0")(V2223!V# >9$T1GTQ^FWJGZM.M62>A?2# )^BK=V52.=Y]Y+7*;)=UW90

M#W7W9N\WOD6MNF5J/H!Q4>@#C[-M7B_\*)O3;F/HIG?T92Y?H*J?H3D;I5@O

MIQR=C#J3!%BF4ZRN=XY=A*QS34E13L+VW[&M?8;0?].^\C=ZQ>ZR._6\IQ0Z

ME@>X$'RD=-3K]1N[+MB_9: ?RZ&4M)/6@GWD$>I/%/2%ZD.EWJ+

MP?)6%]0\0Z9UD^)P91SBA:CJOF:&>@+!U5FAGB$_FP3*"8Y55K$ @S5OANVG

M-\M=LU+* X(E.T00?4&((XB14([F[S+R?,FKQ*$K+9F%;#((]")D'@8-7Q=?

MO^%.77K/V2L0RUT&]/\ A'07,&*Q-139[QW'I,WUM&K@@R44+X9A5/'*--K3

M1S*-?=O8B!\@^F2PMWPNZN%/)'\(3H!\SJ48\B/.I\WA^J',+A@HM;=+*C_$

M5:R/(:4B?,'RK66Q3$,2Q;$\1Q7&:R;$,8Q.>;$,5K\0=Y*B>IFD,DLDKR$L

MSLQ)8G4GOS)EIM*$A*1 PCHK&!UQ2U%2C))DSTUM8?@:_\ 9LW\4O\ [T^/

M?^P!7\Q5[PG_IV,U_Q5?\ *9K5!YE=6)5?1D_ ?_[-

M2^E;_P 3C_V9&8.B>0/45TFR_/FC.7IW&)P9WRWA,;2UE5E/$5CJ)JF&-+M(U!-3AV11?RY)

M'_OI\6D&0A1&GU@ D=1/G-3G?\ U(;P

MOV99'=H41!6E)U>DD@'K \HJA>9IGFE>H9FJ&9FG:8DN7)NQ;=K>_>_)Y2!&

M%0"HF3L#ZA^D'U'9"S-2BMRYG7,>(94QVD-OTE)B&6:.

MEE O?7:YL>,.G&MBM/ S6JLJ_!KZ#_P"=CU8TF?,4HC498Z%T+YWJ))$+1-B]2318

M;&3;1@S25"?&'E'#A6Q4?\:/_J]_'?\ P7,O?^4\G/-;*\:#C\)3_LX-Z?\

M_P 2O_V"<8YMS97A3C^*_P!#LS](_6)U'S%7X5+#D_J_4?YP\F8[M8T]4:J*

M,UT0?51+#5;PR7N%*,0 Z\\V

MKP'#,JY*J$?'LT9=Z:T5?)48C!A2G$W>KEJ9ZE_EZ<0>>P0*H";G)"Z:2@"M

MS59G+UJMA/U3?]F4_2S_ -['+O\ T@Q?C*?NK=:]G'JU6PE^/Q_S%_IG_P"]

M;F?_ ,JL-XTU6S58/X;EU[*T*&O\ &'_ZORZG?]ZW

M+/\ Y8*7FF]E;-#5^!+_ -7K_

MU-_CGJ]2*ZA=-^G_ %:REBN0^J&2L*ZA9+QQ/(Q?*VMZM:X.H(/%N7YE<6CP=864+&PI)!]HI#F.66]XR6GT)6@[0H CV&J@>H__"?3

M\-+/U?-B.%=-\>Z735#>=/#TXS-B*4Y8FYVPXT<2CC!_PQJH'@!R7\M^H+>6

MW3"G$N?XR1\4Z??4.YE]/.[%PJ4M*;_Q5'X*U>Z@\P__ (3=?AU454E14U'4

M#%HE#!J'$,ST:Q-<6!)I)0@=T/\T_-1HN;^FK=M)D]Z

M?-0^215@_IQ_#+]"_I1Q:CS+T4].^"X'G+#SYM#GK,35F8,;II"NQI*:MQZ:

MLEIF87!\@H+$BUCR/=X^TW/EDBD4$J#=6!X$\KS1^RN$/L*TN(,@]!]:%N:Y7;WMNMA].IM8@CI'IC5>

MO_#*WX7W_68$)W7[:6X?;M[\

M9KE"5BS>+87$P 9C9M!Z:#^\NXN4YPI"KQD.%$Q)(B=NPCHH(NEWX4OX?71;

MJ#E3JITP]->&92S_ )(JEQO*N9*/$\PS2T=4BL@D5*K$)8V(#'1E(X;YIVK;

MP7MNMA^Y*FUB"(3B/04495V3;O65PA]BU"7$&095@?5458%64='B-'58?B%+

M'74%=&]'74-8BRPS0RJ4='1P5964D$$6(Y'Z%E)!!@BI"6@*!!$@U5IUB_!2

M_#5ZT8C68WC'IMH,DX]6EGEQ/I+78GEB(%E()6APJ>*A!N0U_E[W'Q-Y2R?M

MJWELDA*;DK2."P%>\C5[ZBK.>Q'=F]45*M@A1XH)3[@=/NH$\&_X3R_AFX97

M1U=;T\S+F*G2V["\9S=C"0/[P.IP]Z67PMHXT/ML>';WU"[S*3 <0GK"!\Y'

MNHC9^G7=A*I+:U=16KY0??5CGI\]$WI.]*J2-Z?N@F7>FN(SQ_)U.9,*H_F,

M:FA-SY#?;-LU_P"*[A3@Z"83_I1 ]U23N[N/E&4_

M\26Z6ST@2K_3&5>^B6?CP?\ 9J7U4_\ B#_^S(R_P:=A'_3UVO\ G_\ *:Z!

M/;Y_TZ5W_N?_ "JBOG-\Z+US=KZ$.7?PB?07ZM_37Z9"=0\1Z=9*

MEQ7/W3.KJ,OXC72/EJB+25BT)%/52FP_2SPO)86W6TYSYN.UW/LHS*Z:9>EL

M.KA*AJ \1V3B!U @5T0M^Q_(,XRRU=?8APM(E224D^$;8P)ZR">NLG3+_A/G

M^&QTZQNDQW$L@9@ZIS4,HK*7#NIN8JF>BWKM*B2GPE,/25 5OLE#*;D,"+ :

MS/Z@MY;E!2EQ+7:'*64\N4\>$Y?RSEJE@H:"AI85VI#!3TRI'&BCLJ@ DD[:FFTM&F&TMMI"4)$ 0 .@ ;*^7]^()_P!7Z^MS_P *]U*_

M]C/$>=/NS[_E@V/^T-?[XFN6W:'_ ,M^^_V]W_?U5>[_ ,)[_2GZ=_5GT3]8

MN1O4/THPOJ?@%)C.3YL*.-1R15V'R38?B\;R45=1O#54SL+ M#*I-A?MR"/J

M#WKS'*;VS=M'2VHI7,;#BG:#(/J*GOZ=]TLMS>QO6KQE+B0I$3M&"MA$$>A%

M6PR?\)R_PWWQU<77"\[0X>K%SE:/-3&@8&_NEWI6JK"_A/?3OWO% ^HS>3N]

M,MSTZ,?C'NJ6C]-V[7>:H7?',\X="[QXN$;!L \

MDB /08\:E7=CF_5W(N%]

M1LB8^HCQ;*V;J2&MI)2AW(X28';(A]Y)%LR-8J01?A3E>;7-B^EZW)473K,>6*>

MJ8RK@N 9LQ"/N

M@8_X96_"^_[A)PC_ ,?&:?\ SZC_F;5[$?X-$O^PENM_S)I]J_P#"

MH^W1;HKTO]._3/+71WHQE*'(O37)_P Y_5O*M!-55$5+_,,0GQ2HVR5LLTIW

MU%3(YW.;%K"PL. +.LZNLQN57%RO6ZJ).&, ;(&P 4/\DR2URZU3;VR-#29

M@8X223MD[230IH[,N(YUSWZ>:+!TLD+.S"Y8W-Y-R#MAWBRUH-M7!*!L"@%1Y$@D#J!

MBHOW@[&MW,R=+KML L[2DE,]9"2 3UD34?H;^#7^'+Z?\>H&

M/'44&/=3J[$\S&&6)1LDCI<8J)Z1)%8;PZP!@QN"++:V>=LF\>8-EMRY*4'@

MD!/O2 ?2:KD78ONWE[@4K#B2(I>1V:RJ +Z #C5KVP;R,-);1=*"4

M@ "$X 8#^&G;KL]V8YNM*[QTN*2($

M@"!Z 4*-VMS\MR="D6;0;2HR8),GU)H&/^&OO0;_ -P[8;_X\L?_ /._@>UF

MA+%&2Z*^GWHYZ=L!Q7+'1?(\&1,!QRL_GV*X=03UM0LU684I_,)K9IF!V1J+

M @:=N5))KU!3U-]!GI&ZQYVQKJ-U)Z)X?F?.N8C V-X]-58K3R5+4]/'21LZ

M4=5"EQ'$JW"W-M;GFPLUZA*Z)>FSH=Z(

M_/1=,L2P^G.^^$T69<=^7NUK:S5,DHVVTL_TWY;O#6HHT?3[T9>EWI5D[-F1

M,@=&,(R[E[/>&5F3,XM"*F?$<2PJOA>GGI9\1JI9:QXW1R+&;3N+'7FBHUN@

MD_X:^]!O_2Y:G$$@I9*595B*R15"S':)W^TY[\KJ->H"_^&OO0;_W#MAO_CRQ_P#\

M[^6UFO10Y];O2IZ?O4?59>K>MG3:ES[594CJ:7+TV(5.(4YIHZMHWF"_(U$

M.XQ+]J_;3E0HBO4'60OP^O1UTPSCE_/^0^A]!EW.&5:@8I@&-TU=C,DE-4*I

M4.JU%9(A-F/VE(YLK->IWZJ^ACTH];\ZXCU%ZJ='*+-^=,6CIZ7$<=K*W%H9

M)8Z2!::(%*2KB0;40#1?#7G@HBO4[]%_1MZ:/3SFBOSIT:Z4TF1$K6U,R &2FC:X%_=[VOSQ437J#K,'X;GHCS5CV-YGQ_H

M%A^)8]F.LJ<>QO$9<0QQ6J*NLF:HFD(CK54%WH;.B/IIZ&^G

M"ES#1=$^G]/D*ES7)356882\JX5\M

MX3"TCI2T&'TZ4E/"K2L[D)'&J@L2=-23RE>I_P">KU?_U=_CGJ]7N>KU>YZO

M5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU!#UXZ#]*

M/4UTHS5T0ZWY5_KMTOSM\C_6?+'SV)8;\S_+<2I\7IO])PBHI:A-E12QO[DB

MWVV-U)!-\ASZ[RR[1KW/5ZOKW/5ZOKW/5ZOKW/5ZOKW/5ZOKW/5ZOKW/5ZO

MKW/5ZOKW/5ZOKW/5ZOKW/5ZOK__6

MW^.>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>

MKU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>Y

MZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[

MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7

7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7_]D!

end

weixin_39968801

关注

0
点赞
踩
0

收藏

觉得还不错? 一键收藏
0
评论
signature=06e97a2b16840469a54f58154cc3c417,Document

0001628280-20-010239.txt : 202007070001628280-20-010239.hdr.sgml : 2020070720200707160511ACCESSION NUMBER:0001628280-20-010239CONFORMED SUBMISSION TYPE:S-8PUBLIC DOCUMENT COUNT:5FILED AS OF DATE:20200...
复制链接

扫一扫